Developer docs
API playgroundTry for free, no card

Search company profiles

RHP

Full company profile

uuid00hjld4

Namestring
RHP
Legal namestring
河南润弘制药股份有限公司
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司, "RHP") is a Chinese integrated pharmaceutical manufacturer founded in 1970 and headquartered in Xinzheng City, Henan Province. The company holds over 240 drug approval numbers across chemical drugs, Chinese patent medicines, and big-health product categories, with therapeutic focus on cardiovascular and cerebrovascular disease and TCM analgesic products. It is widely recognized as one of China's largest small-volume injection manufacturers; its portfolio spans injections, capsules, tablets, and lotions, including the market-leading Vinpocetine Injection ("Runtan" brand, ~70% domestic share), Atropine Sulfate Injection (first-rank winner in China's 9th national volume-based procurement), Furosemide Injection (passed generic consistency evaluation), and a newly NMPA-approved Epinephrine Hydrochloride Injection for emergency rescue indications. The product mix is distributed across over 240 SKUs serving cardiovascular, pain management, anti-infective, and rescue indications.

RHP's production platform is centered on the Runhong Pharmaceutical Industrial Park — a 400-acre site in the Xinzheng New Port Industrial Cluster opened in November 2020 after approximately RMB 1 billion (~US$150M) of investment and comprising 11 modernized production lines covering small-volume injections, oral solid dosages, Chinese medicine decoction pieces, and freeze-dried powder injections. The technological foundation includes fully automated small-volume injection production systems, industrial AGV transport, automated high-rack warehouse storage, fully automated TCM extraction systems, online industrial wastewater monitoring, and a "code-based release" tracking system for end-point quality surveillance. Subsidiary structure spans Henan Runhong Bencao Pharmaceutical Co., Ltd. (TCM formulas and granules), Henan Runhong Pharmaceutical Sales Co., Ltd. (distribution), Henan Jingkang Pharmaceutical Co., Ltd. (API manufacturing, integrated via 2019 strategic cooperation), Henan Lixiang Enterprise Management Co., Ltd., and Hubei Jintaiyuan Biomedicine Co., Ltd. (biological medicines).

The revenue model is B2B drug manufacturing and sales. GTM combines a direct sales force with channel/distributor partnerships — most notably a recent strategic alliance with Jiuzhou Tong Group, which provides a national modernized logistics network and professional hospital pure-sales system. Pricing is materially shaped by China's national volume-based procurement (GPO) policy, with RHP bidding into multiple batches via consolidated tender and securing first-rank positions in key batches. End customers span public/private hospitals, retail pharmacies (chain and independent), and grassroots clinics across China. Marketing channels include national drug trade fairs (e.g., 药交会), academic exchange programs with healthcare institutions and universities, and mainstream media coverage via Xinhua, Henan Daily, and industry publications. RHP filed an A-share IPO tutoring record with CITIC Securities via the Henan Securities Regulatory Bureau in February 2019; the listing process has not yet resulted in a completed IPO as of the available data.

Short descriptiontext

Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司) is a Chinese integrated pharmaceutical manufacturer, one of China's largest small-volume injection producers, holding 240+ drug approvals spanning cardiovascular, TCM, and emergency-rescue products, and serving hospitals, pharmacies, and clinics nationally via direct sales and distributor networks including Jiuzhou Tong Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZhengzhou, China
HQ citystring
Zhengzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small-volume injections, cardiovascular pharmaceuticals, generic drug manufacturing, traditional Chinese medicine, pharmaceutical formulations
Industry2 codes
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1药品生产与销售
TypeOne Time License
Description

润弘制药主要通过研发、生产和销售药品获取收入,产品涵盖中成药、化学药、大健康等领域。拥有240余种药品批准文号,重点聚焦心脑血管类和中药疼痛类产品,业务覆盖全国大部分医院、药店和诊所。

runhong-pharm.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1国家集中带量采购(国采)
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

公司积极参与国家组织药品集中带量采购,地塞米松磷酸钠注射液和硫酸阿托品注射液在第九批国采中第一顺位中标

runhong-pharm.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Henan Runhong Pharmaceutical Co., Ltd. (RHP) is an integrated pharmaceutical manufacturer engaged in the R&D, production, and sale of small-volume injections, capsules, tablets, and lotions. The company holds over 240 drug approval numbers and focuses on cardiovascular drugs and traditional Chinese medicine (TCM) pain products. RHP produces generic formulations including Vinpocetine Injection, Nitroglycerin Injection, and Epinephrine Hydrochloride Injection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 小容量医用水针剂占全国市场份额约30%
+2 more records
Product overview1 text field

RHP (润弘制药, Henan Runhong Pharmaceutical Co., Ltd.) operates as an integrated pharmaceutical manufacturer offering a broad portfolio of chemical drugs and traditional Chinese medicines across multiple dosage forms. The company holds over 240 drug approval numbers covering cardiovascular, pain management, anti-infective, and other therapeutic areas. The product portfolio is organized into four main dosage form categories: small-volume injections (注射剂, representing the company's core strength with 11 production lines), capsules (胶囊剂), tablets (片剂), and lotions (洗剂). Key products include the market-leading Vinpocetine Injection (润坦, ~70% domestic market share), cardiovascular drugs such as Nitroglycerin Injection and Epinephrine Hydrochloride Injection, TCM products including Gandan Shukang Jiaonang and Chaihu Injection, and commonly used injectables such as Dexamethasone Sodium Phosphate Injection, Furosemide Injection (which passed generic consistency evaluation), and Atropine Sulfate Injection (first-ranked winner in the 9th national volume-based procurement). RHP's subsidiary Henan Runhong Bencao Pharmaceutical Co., Ltd. produces TCM formulas and granules, extending the portfolio into Chinese herbal medicine.

Product and service2 records
1Vinpocetine Injection (长春西汀注射液)
CategoryCardiovascular Drug / Small-volume Injection
2Nitroglycerin Injection (硝酸甘油注射液)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1九州通集团
Strategic tier核心TypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-22
Description

九州通集团作为国内领先的医药分销企业,拥有覆盖全国的现代化医药物流网络和专业的医院纯销体系。双方围绕第十二批国家组织药品集中带量采购品种展开合作,并就中风回春片、归脾丸等中成药品种的市场推广与渠道合作达成重要共识。

runhong-pharm.com
2创泰生物
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

润弘制药与创泰生物举行战略合作签约仪式,双方将携手并进,共绘生物医药新篇章。

runhong-pharm.com
3大道隆达
Strategic tier一般TypeStrategic or Co-development PartnerAnnounced on2023-04-29
Description

润弘制药与大道隆达举行战略合作伙伴签约仪式,建立长期战略合作关系。

runhong-pharm.com
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2022-09-23
Description

润弘制药与郑州大学药学院举行校企合作签约暨授牌仪式,双方将在人才培养、科研合作等方面开展深入合作。郑州大学教务处副处长、药学院执行院长等出席仪式。

5中关村亚太生命科技研究院
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2020-11-12
Description

双方就生命健康领域打造可持续发展战略规划合作举行签约仪式,围绕人才引进、技术转化、项目研发、共建生命科学园等项目展开合作,旨在生物医药领域进行全方位合作,把润弘制药工业园建成全国领先的小容量注射剂生产研发基地。

runhong-pharm.com
6浪潮软件
Strategic tier重要TypeTechnology or IntegrationAnnounced on2019-03-06
Description

河南润弘制药与河南浪潮软件合作实施"集团管控型"ERP项目,打造企业信息化管理标杆工程,提升公司整体信息化水平。

runhong-pharm.com
Strategic tier一般TypeStrategic or Co-development Partner
Description

与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线,开展技术研发合作。

8哈尔滨工业大学
Strategic tier一般TypeStrategic or Co-development Partner
Description

与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线,开展技术研发合作。

runhong-pharm.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Shanghai Pharmaceuticals Holding (上海医药)
TypeBroad incumbent
Description

One of China's largest integrated pharma groups spanning branded drugs, generics, TCM, and distribution. Comparable as a broad incumbent in cardiovascular and generic injectables, with substantially larger scale.

TypeBroad incumbent
Description

Diversified Chinese pharma incumbent spanning innovative drugs, generics, biologics, and diagnostics. Comparable as a broad incumbent with overlapping cardiovascular and injection franchises.

TypeOthers
Description

Strategic distribution partner of RHP and one of China's largest pharmaceutical distributors. Included as a channel/ecosystem peer given its role in RHP's national channel strategy.

4Salubris Pharmaceuticals (信立泰)
TypeDirect peer
Description

Chinese pharma with strong cardiovascular drug portfolio including Telmisartan (also produced by RHP) and similar VBP participation; comparable in therapeutic focus and channel dynamics.

5China Resources Double-Crane Pharmaceutical (华润双鹤)
TypeDirect peer
Description

Major Chinese generic injectable drug manufacturer with similar focus on small-volume injections and core cardiovascular product portfolio. Directly comparable in production-line structure, VBP exposure, and channel mix.

6Sichuan Kelun Pharmaceutical (科伦药业)
TypeDirect peer
Description

Leading Chinese injectable drug manufacturer with strong small-volume and large-volume injection manufacturing capabilities. Most direct peer on production technology and VBP-driven generic injectables.

7China Grand Pharmaceutical and Healthcare Holdings (远大医药)
TypeBroad incumbent
Description

Hong Kong-listed Chinese pharma with broad cardiovascular, anti-infective, and emergency-care injectable portfolio. Overlapping product categories and similar channel exposure.

8Livzon Pharmaceutical Group (丽珠集团)
TypeDirect peer
Description

Diversified Chinese pharma combining chemical drug injections, TCM, and biochemicals. Comparable in product mix spanning small-volume injectables and TCM preparations.

9Jichuan Pharmaceutical (济川药业)
TypeEmerging player
Description

Chinese pharma with notable TCM and chemical drug portfolio including pediatric and pain-management categories. Comparable in TCM/chemical drug blend, though with different dosage-form mix.

10Humanwell Healthcare Group (人福医药)
TypeDirect peer
Description

Chinese pharmaceutical manufacturer with overlapping therapeutic portfolios in cardiovascular, anti-infectives, and emergency-care injectables, plus similar generic-drug and channel structure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RHP

Pharmaceutical Manufacturingrunhong-pharm.com

Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司) is a Chinese integrated pharmaceutical manufacturer, one of China's largest small-volume injection producers, holding 240+ drug approvals spanning cardiovascular, TCM, and emergency-rescue products, and serving hospitals, pharmacies, and clinics nationally via direct sales and distributor networks including Jiuzhou Tong Group.

What RHP does

Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司, "RHP") is a Chinese integrated pharmaceutical manufacturer founded in 1970 and headquartered in Xinzheng City, Henan Province. The company holds over 240 drug approval numbers across chemical drugs, Chinese patent medicines, and big-health product categories, with therapeutic focus on cardiovascular and cerebrovascular disease and TCM analgesic products. It is widely recognized as one of China's largest small-volume injection manufacturers; its portfolio spans injections, capsules, tablets, and lotions, including the market-leading Vinpocetine Injection ("Runtan" brand, ~70% domestic share), Atropine Sulfate Injection (first-rank winner in China's 9th national volume-based procurement), Furosemide Injection (passed generic consistency evaluation), and a newly NMPA-approved Epinephrine Hydrochloride Injection for emergency rescue indications. The product mix is distributed across over 240 SKUs serving cardiovascular, pain management, anti-infective, and rescue indications.

RHP's production platform is centered on the Runhong Pharmaceutical Industrial Park — a 400-acre site in the Xinzheng New Port Industrial Cluster opened in November 2020 after approximately RMB 1 billion (~US$150M) of investment and comprising 11 modernized production lines covering small-volume injections, oral solid dosages, Chinese medicine decoction pieces, and freeze-dried powder injections. The technological foundation includes fully automated small-volume injection production systems, industrial AGV transport, automated high-rack warehouse storage, fully automated TCM extraction systems, online industrial wastewater monitoring, and a "code-based release" tracking system for end-point quality surveillance. Subsidiary structure spans Henan Runhong Bencao Pharmaceutical Co., Ltd. (TCM formulas and granules), Henan Runhong Pharmaceutical Sales Co., Ltd. (distribution), Henan Jingkang Pharmaceutical Co., Ltd. (API manufacturing, integrated via 2019 strategic cooperation), Henan Lixiang Enterprise Management Co., Ltd., and Hubei Jintaiyuan Biomedicine Co., Ltd. (biological medicines).

The revenue model is B2B drug manufacturing and sales. GTM combines a direct sales force with channel/distributor partnerships — most notably a recent strategic alliance with Jiuzhou Tong Group, which provides a national modernized logistics network and professional hospital pure-sales system. Pricing is materially shaped by China's national volume-based procurement (GPO) policy, with RHP bidding into multiple batches via consolidated tender and securing first-rank positions in key batches. End customers span public/private hospitals, retail pharmacies (chain and independent), and grassroots clinics across China. Marketing channels include national drug trade fairs (e.g., 药交会), academic exchange programs with healthcare institutions and universities, and mainstream media coverage via Xinhua, Henan Daily, and industry publications. RHP filed an A-share IPO tutoring record with CITIC Securities via the Henan Securities Regulatory Bureau in February 2019; the listing process has not yet resulted in a completed IPO as of the available data.

RHP firmographics

Firmographics
Name
RHP
Legal name
河南润弘制药股份有限公司
Website
https://runhong-pharm.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
11–50 employees
Short description
Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司) is a Chinese integrated pharmaceutical manufacturer, one of China's largest small-volume injection producers, holding 240+ drug approvals spanning cardiovascular, TCM, and emergency-rescue products, and serving hospitals, pharmacies, and clinics nationally via direct sales and distributor networks including Jiuzhou Tong Group.
Ownership category
akta.pro rank

RHP industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Small-volume injections
  • Cardiovascular pharmaceuticals
  • Generic drug manufacturing
  • Traditional Chinese medicine
  • Pharmaceutical formulations

Where RHP is headquartered

Location

Headquarters

HQ city
Zhengzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

RHP business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. 药品生产与销售: 润弘制药主要通过研发、生产和销售药品获取收入,产品涵盖中成药、化学药、大健康等领域。拥有240余种药品批准文号,重点聚焦心脑血管类和中药疼痛类产品,业务覆盖全国大部分医院、药店和诊所。

Pricing tiers

ModelBillingPrice
Transaction based/ take rateMulti-year contract国家集中带量采购(国采)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

RHP product offering

Product offering

Core offering

Henan Runhong Pharmaceutical Co., Ltd. (RHP) is an integrated pharmaceutical manufacturer engaged in the R&D, production, and sale of small-volume injections, capsules, tablets, and lotions. The company holds over 240 drug approval numbers and focuses on cardiovascular drugs and traditional Chinese medicine (TCM) pain products. RHP produces generic formulations including Vinpocetine Injection, Nitroglycerin Injection, and Epinephrine Hydrochloride Injection.

Product overview

RHP (润弘制药, Henan Runhong Pharmaceutical Co., Ltd.) operates as an integrated pharmaceutical manufacturer offering a broad portfolio of chemical drugs and traditional Chinese medicines across multiple dosage forms. The company holds over 240 drug approval numbers covering cardiovascular, pain management, anti-infective, and other therapeutic areas. The product portfolio is organized into four main dosage form categories: small-volume injections (注射剂, representing the company's core strength with 11 production lines), capsules (胶囊剂), tablets (片剂), and lotions (洗剂). Key products include the market-leading Vinpocetine Injection (润坦, ~70% domestic market share), cardiovascular drugs such as Nitroglycerin Injection and Epinephrine Hydrochloride Injection, TCM products including Gandan Shukang Jiaonang and Chaihu Injection, and commonly used injectables such as Dexamethasone Sodium Phosphate Injection, Furosemide Injection (which passed generic consistency evaluation), and Atropine Sulfate Injection (first-ranked winner in the 9th national volume-based procurement). RHP's subsidiary Henan Runhong Bencao Pharmaceutical Co., Ltd. produces TCM formulas and granules, extending the portfolio into Chinese herbal medicine.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vinpocetine Injection (长春西汀注射液)
  • Nitroglycerin Injection (硝酸甘油注射液)

Quantifiable outcome

  • 小容量医用水针剂占全国市场份额约30%
  • +2 more outcomes

Companies that use RHP

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

RHP technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

RHP partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered 核心, 重要 and 一般.

  • 九州通集团核心Channel Partner/ Reseller/ Distributor · 22 June 2026九州通集团作为国内领先的医药分销企业,拥有覆盖全国的现代化医药物流网络和专业的医院纯销体系。双方围绕第十二批国家组织药品集中带量采购品种展开合作,并就中风回春片、归脾丸等中成药品种的市场推广与渠道合作达成重要共识。
  • 创泰生物重要Strategic or Co-development Partner · 21 August 2024润弘制药与创泰生物举行战略合作签约仪式,双方将携手并进,共绘生物医药新篇章。
  • 大道隆达一般Strategic or Co-development Partner · 29 April 2023润弘制药与大道隆达举行战略合作伙伴签约仪式,建立长期战略合作关系。
  • 郑州大学重要Strategic or Co-development Partner · 23 September 2022润弘制药与郑州大学药学院举行校企合作签约暨授牌仪式,双方将在人才培养、科研合作等方面开展深入合作。郑州大学教务处副处长、药学院执行院长等出席仪式。
  • 中关村亚太生命科技研究院核心Strategic or Co-development Partner · 12 November 2020双方就生命健康领域打造可持续发展战略规划合作举行签约仪式,围绕人才引进、技术转化、项目研发、共建生命科学园等项目展开合作,旨在生物医药领域进行全方位合作,把润弘制药工业园建成全国领先的小容量注射剂生产研发基地。
  • 浪潮软件重要Technology or Integration · 6 March 2019河南润弘制药与河南浪潮软件合作实施"集团管控型"ERP项目,打造企业信息化管理标杆工程,提升公司整体信息化水平。
  • 浙江大学一般Strategic or Co-development Partner与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线,开展技术研发合作。
  • 哈尔滨工业大学一般Strategic or Co-development Partner与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线,开展技术研发合作。

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

RHP competitors and assessment

Company assessment

Broad incumbents

  • Shanghai Pharmaceuticals Holding (上海医药): One of China's largest integrated pharma groups spanning branded drugs, generics, TCM, and distribution. Comparable as a broad incumbent in cardiovascular and generic injectables, with substantially larger scale.
  • Fosun Pharma (复星医药): Diversified Chinese pharma incumbent spanning innovative drugs, generics, biologics, and diagnostics. Comparable as a broad incumbent with overlapping cardiovascular and injection franchises.
  • China Grand Pharmaceutical and Healthcare Holdings (远大医药): Hong Kong-listed Chinese pharma with broad cardiovascular, anti-infective, and emergency-care injectable portfolio. Overlapping product categories and similar channel exposure.

Others

  • Jointown Pharmaceutical Group (九州通): Strategic distribution partner of RHP and one of China's largest pharmaceutical distributors. Included as a channel/ecosystem peer given its role in RHP's national channel strategy.

Direct peers

  • Salubris Pharmaceuticals (信立泰): Chinese pharma with strong cardiovascular drug portfolio including Telmisartan (also produced by RHP) and similar VBP participation; comparable in therapeutic focus and channel dynamics.
  • China Resources Double-Crane Pharmaceutical (华润双鹤): Major Chinese generic injectable drug manufacturer with similar focus on small-volume injections and core cardiovascular product portfolio. Directly comparable in production-line structure, VBP exposure, and channel mix.
  • Sichuan Kelun Pharmaceutical (科伦药业): Leading Chinese injectable drug manufacturer with strong small-volume and large-volume injection manufacturing capabilities. Most direct peer on production technology and VBP-driven generic injectables.
  • Livzon Pharmaceutical Group (丽珠集团): Diversified Chinese pharma combining chemical drug injections, TCM, and biochemicals. Comparable in product mix spanning small-volume injectables and TCM preparations.
  • Humanwell Healthcare Group (人福医药): Chinese pharmaceutical manufacturer with overlapping therapeutic portfolios in cardiovascular, anti-infectives, and emergency-care injectables, plus similar generic-drug and channel structure.

Emerging players

  • Jichuan Pharmaceutical (济川药业): Chinese pharma with notable TCM and chemical drug portfolio including pediatric and pain-management categories. Comparable in TCM/chemical drug blend, though with different dosage-form mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

RHP compliance and trust

Trust signal

Compliance5 records

RHP financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RHP leadership team

Management profile

Number of profiles

Profiles2 records

RHP subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

RHP funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RHP M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RHP

What does RHP do?

Henan Runhong Pharmaceutical Co., Ltd. (RHP) is an integrated pharmaceutical manufacturer engaged in the R&D, production, and sale of small-volume injections, capsules, tablets, and lotions. The company holds over 240 drug approval numbers and focuses on cardiovascular drugs and traditional Chinese medicine (TCM) pain products. RHP produces generic formulations including Vinpocetine Injection, Nitroglycerin Injection, and Epinephrine Hydrochloride Injection.

Is RHP a public or private company?

RHP is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RHP founded?

RHP was founded in 1970. It employs 11 to 50 people.

Where is RHP based?

RHP is headquartered in Zhengzhou, China, in the Asia region.

How does RHP make money?

One revenue line is on record: 药品生产与销售.

Who are RHP's main competitors?

Broad incumbents on record are Shanghai Pharmaceuticals Holding (上海医药), Fosun Pharma (复星医药) and China Grand Pharmaceutical and Healthcare Holdings (远大医药). Jointown Pharmaceutical Group (九州通) is listed as an others. Direct peers are Salubris Pharmaceuticals (信立泰), China Resources Double-Crane Pharmaceutical (华润双鹤), Sichuan Kelun Pharmaceutical (科伦药业), Livzon Pharmaceutical Group (丽珠集团) and Humanwell Healthcare Group (人福医药). Jichuan Pharmaceutical (济川药业) is listed as an emerging player.

Does RHP have an API?

No public API is recorded for RHP.

What industry is RHP in?

RHP's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals